美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Lite Strategy Inc.

3.16

+0.08502.77%

成交量：88.29萬

成交額：278.65萬

市值：1.04億

市盈率：-0.66

高：3.23

開：2.98

低：2.98

收：3.07

52周最高：9.00

52周最低：1.46

股本：3,283.77萬

流通股本：3,165.72萬

量比：0.28

換手率：2.79%

股息：- -

股息率：- -

每股收益(TTM):-4.7521

每股收益(LYR):2.67

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):1.18

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Lite Strategy Inc.

交易所：

NASDAQ

成立時間：

2000

員工人數：

28

公司地址：

9920 Pacific Heights Blvd.,Suite 150,San Diego,California,United States

官網：

http://www.meipharma.com

郵編：

92121

電話：

傳真：

- -

簡介：

MEI Pharma, Inc.是一家臨床階段的製藥公司，致力於開發新型和差異化的癌症療法。該公司通過收購有前途的癌症藥物來建立管道，並通過臨床開發、戰略合作夥伴關係以及外包許可或商業化（視情況而定）在項目中創造價值。候選藥物包括口服細胞周期蛋白依賴性激酶9抑製劑voruciclib和靶向氧化磷酸化途徑的靜脈注射小分子線粒體抑製劑ME-344。

董事

名稱

職位

Frederick W. Driscoll

Chairman of the Board

Nicholas R. Glover

Independent Director

Thomas C. Reynolds

Independent Director

Charlie Lee

Director

Joshua Riezman

Director

股東

名稱

職位

Justin J. File

Acting Chief Executive Officer, Chief Financial Officer and Corporate Secretary

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LITS/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LITS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LITS\",,,,,undefined,":{"symbol":"LITS","market":"US","secType":"STK","nameCN":"Lite Strategy Inc.","latestPrice":3.155,"timestamp":1757618209991,"preClose":3.07,"halted":0,"volume":882921,"delay":0,"floatShares":31657199,"shares":32837700,"eps":-4.752063,"marketStatus":"交易中","change":0.085,"latestTime":"09-11 15:16:54 EDT","open":2.98,"high":3.23,"low":2.98,"amount":2786495.144316,"amplitude":0.081433,"askPrice":3.16,"askSize":799,"bidPrice":3.15,"bidSize":2108,"shortable":3,"etf":0,"ttmEps":-4.752063,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1757620800000},"marketStatusCode":2,"adr":0,"listingDate":1071723600000,"exchange":"NASDAQ","adjPreClose":3.07,"preHourTrading":{"tag":"盘前","latestPrice":3.2,"preClose":3.07,"latestTime":"09:29 EDT","volume":152376,"amount":480844.0749168,"timestamp":1757597390017},"volumeRatio":0.283695},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LITS\",,,,,undefined,":{"symbol":"LITS","floatShares":31657199,"roa":"--","roe":"--","lyrEps":2.668167,"volumeRatio":0.283695,"shares":32837700,"dividePrice":0,"high":3.23,"amplitude":0.081433,"preClose":3.07,"low":2.98,"week52Low":1.46,"pbRate":"--","week52High":9,"institutionHeld":0.0392,"latestPrice":3.155,"committee":0.450292,"eps":-4.752063,"divideRate":0,"volume":882921,"delay":0,"ttmEps":-4.752063,"open":2.98,"prevYearClose":2.46,"prevWeekClose":4.23,"prevMonthClose":4.86,"prevQuarterClose":2.47,"fiveDayClose":4.27,"twentyDayClose":5.14,"sixtyDayClose":2.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LITS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"LITS","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2025-02-12","symbol":"LITS","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1739336400000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"LITS","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-1.2},{"market":"US","date":"2024-09-19","symbol":"LITS","fiscalQuarterEnding":"2024/06","expectedEps":-1.48,"name":null,"time":"盤後","type":"earning","dateTimestamp":1726718400000,"reportTimeType":"post","actualEps":-1.13},{"market":"US","date":"2024-05-09","symbol":"LITS","fiscalQuarterEnding":"2024/03","expectedEps":-1.38,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LITS\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-16","recordDate":"2023-11-17","paymentDate":"2023-12-06","value":1.75,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LITS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":2214205,"yearFounded":2000,"employeeNum":28,"address":"9920 Pacific Heights Blvd.,Suite 150,San Diego,California,United States","zipCode":"92121","officePhone":"858 369 7100"},"stockCompanyDetail":{"websiteUrl":"http://www.meipharma.com","compareEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.0256},{"period":"3month","weight":0.0803},{"period":"6month","weight":0.1588},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.1128}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"MEI Pharma, Inc.是一家臨床階段的製藥公司，致力於開發新型和差異化的癌症療法。該公司通過收購有前途的癌症藥物來建立管道，並通過臨床開發、戰略合作夥伴關係以及外包許可或商業化（視情況而定）在項目中創造價值。候選藥物包括口服細胞周期蛋白依賴性激酶9抑製劑voruciclib和靶向氧化磷酸化途徑的靜脈注射小分子線粒體抑製劑ME-344。","exchange":"NASDAQ","name":"Lite Strategy Inc.","nameEN":"Lite Strategy Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LITS\",market:\"US\",,,undefined,":{"directors":[{"name":"Frederick W. Driscoll","position":"Chairman of the Board"},{"name":"Nicholas R. Glover","position":"Independent Director"},{"name":"Thomas C. Reynolds","position":"Independent Director"},{"name":"Charlie Lee","position":"Director"},{"name":"Joshua Riezman","position":"Director"}],"executives":[{"name":"Justin J. File","position":"Acting Chief Executive Officer, Chief Financial Officer and Corporate Secretary"}]}}}